FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2905372020> ?p ?o ?g. }

• W2905372020 endingPage "106" @default.
• W2905372020 startingPage "92" @default.
• W2905372020 abstract "Purpose LCB01-0371 is a novel broad-spectrum oxazolidinone antibacterial agent under investigation for the treatment of infection by gram-positive pathogens, including methicillin-resistant Staphylococcus aureus. This study evaluated the safety, tolerability, and pharmacokinetics of LCB01-0371 after a single intravenous (IV) infusion and determined its absolute oral bioavailability at a therapeutic dose of 800 mg. Methods : This study was conducted in 2 parts. The first part was a single-blind, placebo-controlled, escalating single IV dose study (200, 400, 800, and 1200 mg) of LCB01-0371 via 2 different infusion regimens (250 mL over 60 min or 150 mL over 30 min) in 36 healthy male volunteers. The second part was an open-label, 2-way crossover design study in which 8 subjects were randomly assigned to 1 of 2 sequences of a single oral (800 mg) or IV (400 mg) administration of LCB01-0371. Safety assessments were conducted at regular intervals. Blood and urine were serially sampled, and drug concentrations were measured for up to 24 h to calculate pharmacokinetic parameters. Findings LCB01-0371 after IV administration was generally safe and well tolerated up to 800 mg regardless of the infusion regimen. Adverse events were mild, excluding nausea at the highest dose, and resolved spontaneously. After a single IV administration, LCB01-0371 exhibited linear pharmacokinetic properties over the range of 200–800 mg. The elimination t1/2, volume of distribution, and clearance ranged from 1.48 to 1.68 h, 57.74–76.72 L, and 33.17–43.31 L/h, respectively, and they remained unchanged over the corresponding dose range. Cmax, AUC0–last, and AUC0–∞ increased in a dose-dependent manner. The dose-normalized total exposure after single PO and IV dosing were equivalent, with 90% CIs of the geometric least squares mean ratio of 86.6%–110% for AUC0–last and 86.6%–111% for AUC0–∞. The dose-normalized Cmax was not equivalent between oral and IV dosing, with a 90% CI of the geometric least squares mean ratio of 50.0%–105%. The absolute oral bioavailability of LCB01-0371 after a single 800-mg dose was 99.75%. Implications After a single IV administration, LCB01-0371 was well tolerated in healthy volunteers at doses up to 800 mg, and it exhibited linear pharmacokinetic properties. The comparable total systemic exposure between IV and oral administration supports the ability to switch administration routes without a need for dose adjustment. ClinicalTrials.gov identifier: NCT02882789." @default.
• W2905372020 created "2018-12-22" @default.
• W2905372020 creator A5003763805 @default.
• W2905372020 creator A5015855655 @default.
• W2905372020 creator A5022631166 @default.
• W2905372020 creator A5026101027 @default.
• W2905372020 creator A5041556811 @default.
• W2905372020 creator A5057978258 @default.
• W2905372020 creator A5072889309 @default.
• W2905372020 creator A5079033596 @default.
• W2905372020 date "2019-01-01" @default.
• W2905372020 modified "2023-10-13" @default.
• W2905372020 title "Single-dose Intravenous Safety, Tolerability, and Pharmacokinetics and Absolute Bioavailability of LCB01-0371" @default.
• W2905372020 cites W1966189854 @default.
• W2905372020 cites W1976210769 @default.
• W2905372020 cites W2002132121 @default.
• W2905372020 cites W2037702349 @default.
• W2905372020 cites W2079039203 @default.
• W2905372020 cites W2082395198 @default.
• W2905372020 cites W2092196558 @default.
• W2905372020 cites W2104312420 @default.
• W2905372020 cites W2107190810 @default.
• W2905372020 cites W2109812222 @default.
• W2905372020 cites W2123459303 @default.
• W2905372020 cites W2143949361 @default.
• W2905372020 cites W2146190796 @default.
• W2905372020 cites W2146653342 @default.
• W2905372020 cites W2148116709 @default.
• W2905372020 cites W2148488439 @default.
• W2905372020 cites W2151907467 @default.
• W2905372020 cites W2152320283 @default.
• W2905372020 cites W2153039659 @default.
• W2905372020 cites W2156283731 @default.
• W2905372020 cites W2216470261 @default.
• W2905372020 cites W2441171560 @default.
• W2905372020 cites W2746050631 @default.
• W2905372020 cites W2766105671 @default.
• W2905372020 cites W2766746112 @default.
• W2905372020 cites W2801150341 @default.
• W2905372020 doi "https://doi.org/10.1016/j.clinthera.2018.11.009" @default.
• W2905372020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30559004" @default.
• W2905372020 hasPublicationYear "2019" @default.
• W2905372020 type Work @default.
• W2905372020 sameAs 2905372020 @default.
• W2905372020 citedByCount "6" @default.
• W2905372020 countsByYear W29053720202019 @default.
• W2905372020 countsByYear W29053720202020 @default.
• W2905372020 countsByYear W29053720202022 @default.
• W2905372020 countsByYear W29053720202023 @default.
• W2905372020 crossrefType "journal-article" @default.
• W2905372020 hasAuthorship W2905372020A5003763805 @default.
• W2905372020 hasAuthorship W2905372020A5015855655 @default.
• W2905372020 hasAuthorship W2905372020A5022631166 @default.
• W2905372020 hasAuthorship W2905372020A5026101027 @default.
• W2905372020 hasAuthorship W2905372020A5041556811 @default.
• W2905372020 hasAuthorship W2905372020A5057978258 @default.
• W2905372020 hasAuthorship W2905372020A5072889309 @default.
• W2905372020 hasAuthorship W2905372020A5079033596 @default.
• W2905372020 hasConcept C112705442 @default.
• W2905372020 hasConcept C126322002 @default.
• W2905372020 hasConcept C142724271 @default.
• W2905372020 hasConcept C181389837 @default.
• W2905372020 hasConcept C197934379 @default.
• W2905372020 hasConcept C204787440 @default.
• W2905372020 hasConcept C27081682 @default.
• W2905372020 hasConcept C2778375690 @default.
• W2905372020 hasConcept C2780026642 @default.
• W2905372020 hasConcept C2781413609 @default.
• W2905372020 hasConcept C42219234 @default.
• W2905372020 hasConcept C71924100 @default.
• W2905372020 hasConcept C87813604 @default.
• W2905372020 hasConcept C98274493 @default.
• W2905372020 hasConceptScore W2905372020C112705442 @default.
• W2905372020 hasConceptScore W2905372020C126322002 @default.
• W2905372020 hasConceptScore W2905372020C142724271 @default.
• W2905372020 hasConceptScore W2905372020C181389837 @default.
• W2905372020 hasConceptScore W2905372020C197934379 @default.
• W2905372020 hasConceptScore W2905372020C204787440 @default.
• W2905372020 hasConceptScore W2905372020C27081682 @default.
• W2905372020 hasConceptScore W2905372020C2778375690 @default.
• W2905372020 hasConceptScore W2905372020C2780026642 @default.
• W2905372020 hasConceptScore W2905372020C2781413609 @default.
• W2905372020 hasConceptScore W2905372020C42219234 @default.
• W2905372020 hasConceptScore W2905372020C71924100 @default.
• W2905372020 hasConceptScore W2905372020C87813604 @default.
• W2905372020 hasConceptScore W2905372020C98274493 @default.
• W2905372020 hasFunder F4320310848 @default.
• W2905372020 hasFunder F4320321681 @default.
• W2905372020 hasFunder F4320322344 @default.
• W2905372020 hasIssue "1" @default.
• W2905372020 hasLocation W29053720201 @default.
• W2905372020 hasLocation W29053720202 @default.
• W2905372020 hasOpenAccess W2905372020 @default.
• W2905372020 hasPrimaryLocation W29053720201 @default.
• W2905372020 hasRelatedWork W1555144605 @default.
• W2905372020 hasRelatedWork W1970245702 @default.
• W2905372020 hasRelatedWork W1970331292 @default.
• W2905372020 hasRelatedWork W1984317973 @default.

• next